We are less than a month from my upgraded Q4 FINS review as the company is already out with their first quarter of 2026.
Back in February, I announced Biorem as my first mid-year pick of 2026 and it was certainly one of my higher conviction plays recently. I identified an important six week window between their Q4 and Q1 releases where their would be an opportunity for some rather significant share price appreciation. With this early FINS release, that window has shrunk to four.
As of this morning, Biorem is up 38% from the February Seal of Approval pick, and just 17 cents shy of the $3.73 price target I set at the time.
What I had wondered back in February is if their Q1 financials would turn into a “sell the news” event. I felt that depended on if they could re-fill that backlog along with the anticipated revenue increases they would have over their first three quarters.
Their earnings headlines do indeed suggest a new record backlog, so does this now turn into a longer term hold? Let’s dive in.